Citations

Showing 10 of 108104 citations.

Disseminated High-grade Glioma in a Long-term Survivor of Medulloblastoma
Porter, Alyx B. , Nelson, Kent D., Raghunathan, Aditya , Mrugala, Maciej , Raghunathan, Aditya , Sio, Terence T. , Bendok, Bernard R.

Mayo Clinic

The Neurologist | October 30, 2018 | Volume: 23 | Issue: 6 | Pages: 191-193

10.1097/nrl.0000000000000199 | PMID 30379742 Get It

We describe a gentleman diagnosed with a posterior fossa medulloblastoma in 1998, successfully treated with craniospinal radiation therapy (RT) and posterior fossa RT boost, followed by 12 months of adjuvant chemotherapy. Nineteen years later, at the age of 28, the patient presented with multiple cranial neuropathies and was found to have disseminated high-grade glioma with leptomeningeal dissemination. In addition to the salient features of this case, we provide a brief review of RT-induced malignancies and the need for further research regarding surveillance and prevention strategies.
New molecular targets in meningiomas: the present and the future
Venur, Vyshak Alva , Santagata, Sandro , Galanis, E., Brastianos, Priscilla K. , Galanis, Eva, Santagata, Sandro

Mayo Clinic

Current Opinion in Neurology | October 30, 2018 | Volume: 31 | Issue: 6 | Pages: 740-746

10.1097/wco.0000000000000615 | PMID 30379704 Get It

Purpose of reviewMeningiomas, the most common primary brain tumor, have historically been managed with surgery and radiation. Traditional chemotherapy has not been effective. Fortunately, recent advances in genetic sequencing have led to an improved understanding of the molecular drivers in meningioma. This article aims to discuss the diagnostic and therapeutic implications of recently discovered genetic alterations in meningiomas.Recent findingsMany of the recently discovered genetic alterations correlate with distinct clinical phenotypes.SMO,AKTandPIK3CAmutations are enriched in the anterior skull base.KLF4mutations are specific for secretory histology, andBAP1alterations are common in progressive rhabdoid meningiomas. Alterations inTERT,DMDandBAP1correlate with poor clinical outcomes. Importantly, the discovery of clinically actionable alterations in a number of genes, includingSMO,AKT1andPIK3CA,has opened up novel potential avenues for therapeutic management of meningiomas. Overexpression of PD-L1 in higher grade meningiomas also provides preclinical support for the investigation of checkpoint blockade.SummaryThe discovery of genetic alterations has improved our understanding of the natural history and classification of meningiomas. Clinical trials with several novel agents targeting driver mutations are currently accruing patients and they can lead to better treatment strategies.
Proximal Interruption of the Pulmonary Artery
Williams, Eric A., Cox, Chad, Chung, Jonathan H. , Grage, Rolf A. , Rojas, Carlos A. , Williams, Eric A.

Mayo Clinic

Journal of Thoracic Imaging | October 30, 2018 | Volume: 34 | Issue: 1 | Pages: 56-64

10.1097/rti.0000000000000373 | PMID 30376479 Get It

Proximal interruption of the pulmonary artery (PIPA) is an uncommon developmental anomaly resulting in underdevelopment of the proximal portion of the pulmonary artery with preservation of the intrapulmonary segments. Clinical presentation ranges between an asymptomatic incidental finding to massive hemoptysis. When findings suggestive of PIPA are present radiographically, the diagnosis of PIPA can be definitively diagnosed with computed tomography or magnetic resonance pulmonary angiography. Other imaging modalities, such as nuclear perfusion scan and catheter angiography can help in the diagnosis.
Version 3 of the National Alzheimer’s Coordinating Center’s Uniform Data Set
Besser, Lilah M. , Kukull, Walter A. , Chui, Helena C., Galasko, Douglas, Weıntraub, Sandra , Jicha, Gregory A. , Carlsson, Cynthia M., Burns, Jeffrey M. , Rascovsky, Katya, Teylan, Merilee, Beekly, Duane, Bollenbeck, Mark, Monsell, Sarah E. , Zhou, Xiao‐Hua , Thomas, Nicole M. , Robichaud, Elizabeth, Dean, Margaret, Hubbard, Janene L., Jacka, Mary, Schwabe‐Fry, Kristen, Wu, Joylee, Phelps, Creighton H., Morris, John C. , Carlsson, Cynthia M. , Morris, John C , Knopman, David S. , Chui, Helena C. , Quinn, Joseph F. , Sweet, Robert A. , Thomas, George E. C. , Mock, Charles , Jicha, Gregory A

Mayo Clinic

Alzheimer Disease & Associated Disorders | October 30, 2018 | Volume: 32 | Issue: 4 | Pages: 351-358

10.1097/wad.0000000000000279 | PMID 30376508 Get It

Introduction: In 2015, the US Alzheimer’s Disease Centers (ADC) implemented Version 3 of the Uniform Data Set (UDS). This paper describes the history of Version 3 development and the UDS data that are freely available to researchers. Methods: UDS Version 3 was developed after years of coordination between the National Institute on Aging-appointed Clinical Task Force (CTF), clinicians from ∼30 ADCs, and the National Alzheimer’s Coordinating Center (NACC). The CTF recognized the need for updates to align with the state of the science in dementia research, while being flexible to the diverse needs and diseases studied at the ADCs. Version 3 also developed a nonproprietary neuropsychological battery. Results: This paper focuses on the substantial Version 3 changes to the UDS forms related to clinical diagnosis and characterization of clinical symptoms to match updated consensus-based diagnostic criteria. Between March 2015 and March 2018, 4820 participants were enrolled using UDS Version 3. Longitudinal data were available for 25,337 of the 37,568 total participants using all UDS versions. Discussion: The results from utilization of the UDS highlight the possibility for numerous research institutions to successfully collaborate, produce, and use standardized data collection instruments for over a decade.
In Response
Kor, Daryl J. , Warner, Matthew A.

Mayo Clinic

Anesthesia & Analgesia | October 30, 2018 | Volume: 128 | Issue: 1 | Pages: e14-e15

10.1213/ane.0000000000003900 | PMID 30379680 Get It

Liver Anesthesiology and Critical Care Medicine, 2nd ed
Aniskevich, Stephen , Pai, Sher‐Lu

Mayo Clinic

Anesthesia & Analgesia | October 30, 2018 | Volume: 128 | Issue: 1 | Pages: e5-e5

10.1213/ane.0000000000003895 Get It

Dispersion analysis of PoTRA ranked mRNA mediated dysregulated pathways in Breast Invasive Cancer from a TCGA Pan-Cancer study
Linan, Margaret, Dinu, Valentin

Mayo Clinic

No container title available | October 30, 2018 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.7287/peerj.preprints.27306v1 Get It

Background. Our publication of the new pathways of topological rank analysis (PoTRA) algorithm demonstrated a novel approach for using the Google Search PageRank algorithm to analyze gene expression networks to identify biological pathways significantly disrupted in hepatocellular carcinoma. In order to apply the PoTRA algorithm to analyze other cancer gene expression data sets, of various sizes and normal:tumor ratio composition, two important questions must be answered: 1. What is the optimal normal:tumor sample ratio?; and 2. What is the minimum number of samples that should be used for PoTRA analysis? To address these questions, the average standard deviation (SD) in PoTRA-ranked mRNA mediated dysregulated pathways was studied using randomly sampled data sets with various normal:tumor ratios and sizes drawn from the TCGA Breast Invasive Carcinoma (TCGA-BRCA) project. Methods. To identify the optimal normal:tumor sample ratios, the SD analysis used random combinations of 1:N unbalanced normal:tumor data sets: (1:1, 1:2, 1:3, 1:5, 1:7, 1:9). To identify the minimum sample size, random resampling of normal and tumor samples of various sizes are used: (3 vs 3), (5 vs 5), (10 vs 10), (25 vs 25), (50 vs 50), (75 vs 75), (100 vs 100), and (113 vs 113). Results. This analysis suggests that the 1:1 ratio achieves the lowest average rank variation and that the minimum sample size of 50 normal and 50 tumor samples reaches a steady state in the average rank variation. Conclusion. In conclusion, future applications of the PoTRA algorithm to analyze gene expression data sets such as TCGA should use balanced data sets as well as a minimum sample size of 50 for both normal and tumor to ensure the most robust performance.
Adults with eosinophilic oesophagitis identify symptoms and quality of life as the most important outcomes
Balsiger, Lukas Michaja , Hafner, David , Kuehni, Claudia E. , Zwahlen, Marcel , Trelle, Sven , Godat, Sébastien, Biedermann, Luc , Greuter, Thomas , Vavricka, Stephan R. , Straumann, Alex , Schoepfer, Alain , Schoepfer, Alain M , Safroneeva, Ekaterina

Mayo Clinic

Alimentary Pharmacology & Therapeutics | October 30, 2018 | Volume: 48 | Issue: 10 | Pages: 1082-1090

10.1111/apt.15000 | PMID 30375682 Get It

SummaryBackgroundWell informed patients who are in cohesive partnership with physicians and who have realistic expectations towards therapy are more likely to be adherent, which results in better disease control.AimTo assess which therapy goals adults with eosinophilic oesophagitis consider relevant.MethodsFollowing refinement during three focus groups, a study brochure and questionnaire were sent to 148 patients. Patients ranked the importance (five levels) of short‐term (in the next 3 months) and long‐term (≥1 year) treatment effect on symptoms, quality of life (QoL), histologically‐detected inflammation and fibrosis, endoscopically‐detected inflammation, and stricture formation as well as achieving histological remission while asymptomatic. Patients’ characteristics associated with treatment goals were identified using logistic regression.ResultsOf 109 respondents (mean age 43 years), 85 were men. Over 90% chose symptoms and QoL improvement as important short‐ and long‐term therapy goals. A greater proportion attributed more importance to long‐term reduction in endoscopic (90% vs 73%, P < 0.001) and histological (81% vs 62%, P = 0.002) inflammation, and histologically‐detected fibrosis (79% vs 64%, P = 0.018) when compared to short‐term reduction in these features. Patients (88%) ranked achieving histological remission while being asymptomatic as important. Gender, therapy use, education level, QoL, symptom severity, and history of dilation were associated with patients’ choice of treatment goals.ConclusionsPatients attributed most importance to improvement in symptoms and QoL. Reduction in biological activity was judged less important, but more relevant in the long‐ compared to the short‐term.
Cardiac CT Angiography in Carcinoid Heart Disease
Alsaad, Ali A. , Rojas, Carlos A.

Mayo Clinic

Radiology | October 30, 2018 | Volume: 290 | Issue: 1 | Pages: 32-32

10.1148/radiol.2018181966 | PMID 30375927 Get It

Resurgence of Eating Disorders with Olanzapine
Wu, Kelly L. , Lorenz, Amanda K., Christensen, Kelly J., Feely, Molly A., Carey, Elise C. , Strand, Jacob J. , Christensen, Kelly

Mayo Clinic

Journal of Palliative Medicine | October 30, 2018 | Volume: 22 | Issue: 2 | Pages: 231-233

10.1089/jpm.2018.0364 | PMID 30376403 Get It